CGM analytics and clinical-workflow software developer
Glucose-data software connecting clinician panel review with a separate patient app. Endobits supports triage and draft documentation; Companion interprets supported feeds and shares reports with an invited clinic. The current offer requires product-specific validation, privacy and regulatory review.
Vancouver digital-health developer with two connected Endobits products: a clinician web platform for CGM panel review, follow-up prioritization and draft care documentation, and the separate Companion patient app for interpreting supported glucose feeds and sharing reports with an invited clinic. Commercial routes include provider and payer software packages plus a free patient app. The company describes a September 2026 Virtual Clinic launch; Moms+ remains a California-first pregnancy-programme waitlist. These stages do not establish accepted Canadian care, software clearance or independently demonstrated clinical outcomes.
Operating context
Clinicians use a web platform to rank CGM panels, review trends and approve draft notes. Provider pages advertise EHR links; the 2024 Endobits V5 announcement describes GPT-4-assisted charting with ADA context. RPM/CCM documentation and USD packages are U.S. commercial routes whose eligibility remains with the provider. Companion has different interfaces and safety scope: direct Dexcom access is for U.S. accounts, Libre enters through Apple Health, Nightscout uses the patient’s hosted URL, and Eversense remains coming soon. Default app health processing is local; optional Health Sync copies authorized categories to U.S. servers. The 2020 Diabits paper is observational and employee-authored; current longer-horizon reports and named panel references are offered privately. Deployment therefore needs product-, country- and function-specific integration, data and clinical review.
Canadian footprint
Corporations Canada lists active Bio-Conscious Technologies Inc., corporation 922906-0, under the CBCA with incorporation on 22 March 2015 and business number 806014585RC0001. Its registered office is Suite 3000, 1055 Dunsmuir Street, Vancouver, BC V7X1K8; the company publishes a separate Vancouver postal box. These establish legal and mailing presence, not a laboratory, operating clinic or additional facility. The company’s 2016 founding narrative describes a different milestone, so the dossier leaves founded year unset.
Vancouver, British Columbia is the published city-level context for Bio-Conscious Technologies. It does not imply a street address or exact facility location.
Bio-Conscious offers a pathway from supported glucose feeds to human review: Endobits prioritizes clinician panels and assists documentation, while Companion provides patient interpretation and clinic sharing with different country and low-range limits. Three government records establish distinct development and commercialization agreements. The decisive buyer questions are the selected product and connector, evidence for the required forecast horizon, data-sharing configuration and software-specific regulatory status. App distribution and supplier service-launch statements do not resolve accepted Canadian clinical delivery or independent effectiveness.
Interpretation of the public record. Not qualification, endorsement or evidence of buyer interest.
CGM analytics and clinician care-workflow software
Clinician panel triage and assisted documentation from CGM feeds, with version-specific validation and integration requirements.
Read technical summary
Endobits brings CGM feeds into a clinician web workflow for ranked panel review, trends, follow-up prioritization and draft charting. Provider pages market EHR links and RPM/CCM documentation; the V5 announcement describes GPT-4-assisted notes using ADA context. Clinicians retain judgment and billing responsibility. The company markets longer-horizon forecasts, but its public performance page separates shorter-horizon Diabits research from ongoing internal validation. Its non-device CDS position requires function- and version-specific review against current FDA guidance; sensor clearance and clinician oversight do not independently establish software clearance.
Evidence of maturity
Commercially marketed provider software with company-reported U.S. panels. Public shorter-horizon research is observational; longer-horizon and outcome evidence remains partly private. Regulatory status requires assessment by function and version.
Commercial availability
Provider and payer packages are advertised; current named acceptance is offered through private references. Permissions, EHR connectors and jurisdiction-specific billing terms require agreement.
Core features
CGM-feed aggregation supports ranked patient panels, trends and prioritization of follow-up.
Provider pages advertise eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko links; the accepted connector configuration requires agreement.
Endobits V5’s 25 April 2024 announcement describes GPT-4-assisted chart drafts using CGM review and ADA guidelines for clinician approval.
Patient CGM interpretation and clinician-sharing application
Patient CGM interpretation and clinic sharing, with explicit connector, low-range and optional data-sync limits.
Read technical summary
Companion is the patient iOS app that interprets supported glucose feeds and shares reports with an invited clinic. Apple’s native record lists version 5.1.0 released on 9 September 2026. Current paths include U.S. Dexcom accounts, Libre through Apple Health and a patient-hosted Nightscout site; Eversense remains coming soon. It never forecasts a low: forecasting stops near low range and prompts a meter check. Health data is normally processed on-device, with an explicit optional Health Sync path to U.S. servers. Availability does not establish regulated medical efficacy or accepted clinical care.
Evidence of maturity
A distributable iOS app at version 5.1.0. Low-range restrictions and connector availability are release-specific; consumer availability does not establish clinical efficacy or a software regulatory determination.
Commercial availability
Free Canadian App Store listing; direct Dexcom connection is currently limited to U.S. accounts. Clinic sharing requires an invitation and permissions; Eversense is described as coming soon.
Core features
Apple’s Canadian lookup lists free version 5.1.0, minimum iOS 16.4 and native release instant 2026-09-09T07:23:46Z.
Public record
Recent activity
Sep 9, 2026
Apple’s native lookup records Companion 5.1.0 released on 9 September 2026 at 07:23:46 UTC, with minimum iOS 16.4. Separately, the company describes Endobits Virtual Clinic as launched in September 2026, without a native launch day or named accepted Canadian clinic. Its Moms+ article dated 15 August remains a waitlist with planned California-first enrollment. These are distinct app-release, supplier service-launch and planned-programme milestones.
Endobits is marketed to primary-care, endocrinology and payer buyers through active-patient software packages. Companion 5.1 is offered free through Apple’s Canadian distribution record. Optional patient Watch and payer pilot structures are advertised offers; current named provider acceptance is not supplied publicly.
Financing and disclosed activity
Canadian support records match business number 806014585. PacifiCan discloses a CAD 1,500,000 contribution, agreement PC0012694, from 20 March 2026 to 31 March 2028 for diabetes-AI commercialization; the 11 May 2026 announcement names Endobits. NRC IRAP discloses a CAD 49,420 contribution, agreement 969177, from 15 June to 17 December 2021 for two software components investigating Alzheimer detection using CGM data. CanExport Innovation records a CAD 5,944 grant, agreement 7406831 P007724001, from 22 May to 10 December 2019 for international R&D partnership discussions, including a CAD 281 amendment on 18 July. These distinct agreements do not establish equity investment, full disbursement or clinical validation.
Reported stage
Commercial digital-health software developer
Funding and ownership
PacifiCan REGI contribution
May 11, 2026
$1,500,000
PacifiCan discloses a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, agreement PC0012694, from 20 March 2026 to 31 March 2028 for diabetes-AI commercialization. Its 11 May 2026 announcement names Endobits for intended hospital use in Canada and the U.S. This establishes an agreement and objective, not full disbursement, equity investment or hospital acceptance.
NRC IRAP research-development contribution
$49,420
NRC discloses a CAD 49,420 contribution to Bio-Conscious Technologies Inc., BN 806014585, agreement 969177, from 15 June to 17 December 2021 for two ML software components investigating Alzheimer detection using CGM data. It establishes development funding, not a validated diagnostic product or completed clinical study. Repayment and full disbursement are not established.
CanExport Innovation grant
$5,944
Global Affairs Canada discloses a CAD 5,944 CanExport Innovation grant to the recipient matched by BN 806014585, agreement 7406831 P007724001, from 22 May to 10 December 2019 for international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 18 July 2019. This is the amended disclosed agreement total, not a sales contract or verified cash receipt.
Questions for a first conversation
01
Which intended-use functions and releases have a documented software-specific regulatory classification, and what current QMS evidence supports that configuration?
The company cites a non-device CDS position and future autonomous-function path. Current FDA guidance treats repeated CGM measurements as patterns; classification depends on the actual function, version and intended use.
02
Which named provider has accepted the proposed configuration, and which independent protocol and cohort substantiate its forecast horizon and clinical outcome measures?
Current provider references and longer-horizon reports are offered privately. The public Diabits paper is observational and employee-authored; both historical trial records have UNKNOWN current status and no posted results.
03
Which CGM account, connector, country and EHR permissions are supported for the selected clinician or Companion release?
Provider pages advertise EHR links, while Companion specifies U.S. Dexcom accounts, Apple Health/Libre and Nightscout, with Eversense coming soon. Current Companion forecasts stop near low range rather than predict lows.
04
Will optional Health Sync and clinic sharing be enabled, and which clinician, data-processing agreement and jurisdiction govern the proposed care pathway?
Default app health processing is local, but optional sync copies authorized categories to U.S. servers. Provider terms retain clinician responsibility; Moms+ remains a California-first waitlist rather than accepted care.
Original sources 28 linked records
These records support the organization, its owned capabilities and their reviewed connections. A source count is not a count of independent confirmations.
The 2020 JMIR Diabetes article, published 2020-09-22, studies Diabits using retrospective observational app data. Models use CGM and optional user/context inputs; the described integration paths include Dexcom Share and Nightscout. Its published prediction analysis concerns horizons through 60 minutes, not a 12-hour clinical forecast.
The JMIR paper identifies all three authors as current Bio-Conscious employees and states the work occurred in their employment. The app-use/time-in-range association has selection and confounding limitations; the study does not establish a causal clinical benefit or independent authorship.
The JMIR paper identifies all three authors as current Bio-Conscious employees and states the work occurred in their employment. The app-use/time-in-range association has selection and confounding limitations; the study does not establish a causal clinical benefit or independent authorship.
Supports: Profile · profileData.portfolioScope
The 2020 JMIR Diabetes article, published 2020-09-22, studies Diabits using retrospective observational app data. Models use CGM and optional user/context inputs; the described integration paths include Dexcom Share and Nightscout. Its published prediction analysis concerns horizons through 60 minutes, not a 12-hour clinical forecast.
Supports: Profile · operating context
The JMIR paper identifies all three authors as current Bio-Conscious employees and states the work occurred in their employment. The app-use/time-in-range association has selection and confounding limitations; the study does not establish a causal clinical benefit or independent authorship.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The 2020 JMIR Diabetes article, published 2020-09-22, studies Diabits using retrospective observational app data. Models use CGM and optional user/context inputs; the described integration paths include Dexcom Share and Nightscout. Its published prediction analysis concerns horizons through 60 minutes, not a 12-hour clinical forecast.
Supports: Endobits clinician CGM review and care-workflow platform · maturity
The JMIR paper identifies all three authors as current Bio-Conscious employees and states the work occurred in their employment. The app-use/time-in-range association has selection and confounding limitations; the study does not establish a causal clinical benefit or independent authorship.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The JMIR paper identifies all three authors as current Bio-Conscious employees and states the work occurred in their employment. The app-use/time-in-range association has selection and confounding limitations; the study does not establish a causal clinical benefit or independent authorship.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The 2020 JMIR Diabetes article, published 2020-09-22, studies Diabits using retrospective observational app data. Models use CGM and optional user/context inputs; the described integration paths include Dexcom Share and Nightscout. Its published prediction analysis concerns horizons through 60 minutes, not a 12-hour clinical forecast.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The JMIR paper identifies all three authors as current Bio-Conscious employees and states the work occurred in their employment. The app-use/time-in-range association has selection and confounding limitations; the study does not establish a causal clinical benefit or independent authorship.
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
Supports: Profile · disclosed financing summary
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
Supports: CanExport Innovation grant funding event
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
Supports: CanExport Innovation grant funding event
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
Supports: CanExport Innovation grant funding event
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
Supports: CanExport Innovation grant funding event
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
Supports: CanExport Innovation grant funding event
Global Affairs Canada’s record for BN 806014585 lists a CAD 5,944 CanExport Innovation grant, agreement 7406831 P007724001, 2019-05-22 to 2019-12-10, to support international R&D partnership discussions. The original CAD 5,663 was amended by CAD 281 on 2019-07-18; the total is not a product-sale contract.
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
The same policy describes provider PHI processing as a HIPAA business-associate workflow using BAAs, with possible processing in Canada, the U.S. and other locations. These are company policy representations, not certification or evidence of Canada-only residency.
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Profile · display lead
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Profile · profileData.securityPosture
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Profile · profileData.securityPosture
The same policy describes provider PHI processing as a HIPAA business-associate workflow using BAAs, with possible processing in Canada, the U.S. and other locations. These are company policy representations, not certification or evidence of Canada-only residency.
Supports: Profile · operating context
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · display lead
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · summary
The privacy policy effective 2026-09-07 says Companion normally analyzes health data on the device. Optional Health Sync is off by default; enabling it copies authorized health categories to U.S. servers for stated improvement and clinic-sharing functions. Disabling sync deletes synced health rows.
Bio-Conscious describes Endobits as CGM decision support using Dexcom, Abbott and Senseonics data for forecast-based patient triage, EHR workflow and charting/billing; reimbursement language refers to US Medicare, not guaranteed Canadian payment.
Supports: Profile · description
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Profile · canadian footprint
The company publishes a generic contact route: contact@bioconscious.tech and +1 (236) 235-5295. Its mailing address is PO Box 3707, Vancouver Station Terminal, BC V6B 3Z1; the postal box does not establish an operating site.
Supports: Profile · profileData.portfolioScope
The corporate site says Endobits Virtual Clinic launched in September 2026 and is live in U.S. clinics and on patient phones. No named current clinic or accepted-service evidence is supplied on that page.
Supports: Profile · role descriptor
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Supports: Profile · website url
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
The company publishes a generic contact route: contact@bioconscious.tech and +1 (236) 235-5295. Its mailing address is PO Box 3707, Vancouver Station Terminal, BC V6B 3Z1; the postal box does not establish an operating site.
Supports: Profile · description
The corporate site says Endobits Virtual Clinic launched in September 2026 and is live in U.S. clinics and on patient phones. No named current clinic or accepted-service evidence is supplied on that page.
Bio-Conscious describes Endobits as CGM decision support using Dexcom, Abbott and Senseonics data for forecast-based patient triage, EHR workflow and charting/billing; reimbursement language refers to US Medicare, not guaranteed Canadian payment.
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Supports: Profile · canadian footprint
The company narrative says founded in 2016, whereas the federal record documents incorporation on 2015-03-22. These may describe different milestones; incorporation is the independently verified legal date.
The company publishes a generic contact route: contact@bioconscious.tech and +1 (236) 235-5295. Its mailing address is PO Box 3707, Vancouver Station Terminal, BC V6B 3Z1; the postal box does not establish an operating site.
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Bio-Conscious describes Endobits as CGM decision support using Dexcom, Abbott and Senseonics data for forecast-based patient triage, EHR workflow and charting/billing; reimbursement language refers to US Medicare, not guaranteed Canadian payment.
Supports: Profile · defence posture
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Profile · display lead
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
The company publishes a generic contact route: contact@bioconscious.tech and +1 (236) 235-5295. Its mailing address is PO Box 3707, Vancouver Station Terminal, BC V6B 3Z1; the postal box does not establish an operating site.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The corporate site says Endobits Virtual Clinic launched in September 2026 and is live in U.S. clinics and on patient phones. No named current clinic or accepted-service evidence is supplied on that page.
Supports: Profile · profileData.portfolioScope
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Supports: Profile · current activity
The corporate site says Endobits Virtual Clinic launched in September 2026 and is live in U.S. clinics and on patient phones. No named current clinic or accepted-service evidence is supplied on that page.
Supports: Profile · dual use posture
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Bio-Conscious describes Endobits as CGM decision support using Dexcom, Abbott and Senseonics data for forecast-based patient triage, EHR workflow and charting/billing; reimbursement language refers to US Medicare, not guaranteed Canadian payment.
Supports: Profile · operating context
Bio-Conscious describes Endobits as CGM decision support using Dexcom, Abbott and Senseonics data for forecast-based patient triage, EHR workflow and charting/billing; reimbursement language refers to US Medicare, not guaranteed Canadian payment.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Bio-Conscious describes Endobits as CGM decision support using Dexcom, Abbott and Senseonics data for forecast-based patient triage, EHR workflow and charting/billing; reimbursement language refers to US Medicare, not guaranteed Canadian payment.
The company publishes a generic contact route: contact@bioconscious.tech and +1 (236) 235-5295. Its mailing address is PO Box 3707, Vancouver Station Terminal, BC V6B 3Z1; the postal box does not establish an operating site.
Supports: Profile · operating context
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · technicaldomainslugs
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · summary
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Supports: Endobits clinician CGM review and care-workflow platform · name
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · core features
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · core features
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · core features
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · display lead
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · summary
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · maturity
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · core features
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · capability type
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · maturity
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · name
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits clinician CGM review and care-workflow platform · technicaldomainslugs
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Endobits is a clinician-oriented platform combining continuous glucose monitor data with predictive analytics and patient triage. The product page lists Dexcom, Abbott and Senseonics data compatibility and clinician-facing glucose trends and alerts. The company markets Endobits for clinical workflows; advertised prediction horizons and outcome improvements are vendor claims, not independently established efficacy or blanket regulatory clearance. Clinical teams can scope integration and remote care workflows; Diabits and the forthcoming Moms+ offer are distinct products.
Supports: Endobits clinician CGM review and care-workflow platform · capability type
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Bio-Conscious markets Endobits as a clinician platform that turns CGM data into ranked patient reviews, glucose forecasts, care workflows, and draft documentation for clinician approval. The company positions the product around prevention and ongoing metabolic care.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · maturity
The company positions its clinician decision-support levels 1–3 as non-device CDS under FDA 2022 guidance; autonomous level-4 alerts or closed recommendations are described as a future 510(k)/De Novo path. ISO 13485 QMS status and timing are offered in an investor brief, not as an independently verified certificate or clearance.
Supports: Profile · entity kind
True North Map classifies Bio-Conscious Technologies as a company from its documented legal or institutional role.
Supports: Profile · primary location.latitude
True North Map uses the Vancouver city centroid latitude 49.2827 for a city-level map location.
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Supports: Profile · company stage
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Supports: Profile · current activity as of
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Supports: Profile · commercial status
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · maturity
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · summary
Apple’s Canadian lookup for app 1505619473 returns version 5.1.0 and currentVersionReleaseDate 2026-09-09T07:23:46Z. The current listing names BioConscious Technologies as developer; the lookup gives a free CAD price and minimum iOS 16.4.
The Moms+ announcement dated 2026-08-15 describes a pregnancy glucose programme built on Endobits. It accepts a mailing-list/waitlist signup and says enrollment will open first in California; it does not establish accepted care, a Canadian clinical launch, or current programme outcomes.
Supports: Profile · description
The Moms+ announcement dated 2026-08-15 describes a pregnancy glucose programme built on Endobits. It accepts a mailing-list/waitlist signup and says enrollment will open first in California; it does not establish accepted care, a Canadian clinical launch, or current programme outcomes.
Supports: Profile · profileData.portfolioScope
The Moms+ announcement dated 2026-08-15 describes a pregnancy glucose programme built on Endobits. It accepts a mailing-list/waitlist signup and says enrollment will open first in California; it does not establish accepted care, a Canadian clinical launch, or current programme outcomes.
Supports: Profile · operating context
On August 15, 2026 Bio-Conscious opened the public waitlist for the Endobits-based Moms+ pregnancy glucose programme, with enrollment intended to start in California; waitlist access is not general clinical launch or Canadian deployment.
Supports: Profile · current activity
On August 15, 2026 Bio-Conscious opened the public waitlist for the Endobits-based Moms+ pregnancy glucose programme, with enrollment intended to start in California; waitlist access is not general clinical launch or Canadian deployment.
Supports: Profile · current activity as of
On August 15, 2026 Bio-Conscious opened the public waitlist for the Endobits-based Moms+ pregnancy glucose programme, with enrollment intended to start in California; waitlist access is not general clinical launch or Canadian deployment.
Supports: Profile · current activity
The Moms+ announcement dated 2026-08-15 describes a pregnancy glucose programme built on Endobits. It accepts a mailing-list/waitlist signup and says enrollment will open first in California; it does not establish accepted care, a Canadian clinical launch, or current programme outcomes.
The Care Line page markets an AI phone assistant that can flag clinician handoff, while expressly saying it is not a licensed nurse or physician and does not provide medical advice. This supports an assistant service offer, not independent evidence of licensed clinical care.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Profile · operating context
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · dual use posture
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · profileData.portfolioScope
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · defence posture
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · description
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · display lead
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · role descriptor
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Profile · operating context
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · capability type
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · maturity
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · display lead
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · display lead
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · summary
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · technicaldomainslugs
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · slug
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
The current Companion description says it does not forecast a low: forecasting stops near the low range and prompts a meter check. It distinguishes live, replay and demo views. Corporate pages describing low forecasts or broad Eversense compatibility must be qualified by this version-specific app scope.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · summary
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · name
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
Supports: Endobits Companion CGM interpretation and clinic-sharing app · core features
The Companion listing supports Dexcom U.S. accounts, FreeStyle Libre through Apple Health, read-only Apple Health data and a self-hosted Nightscout URL. Eversense is labelled coming soon. Clinic invite codes enable clinician sharing; an AGP report becomes available after roughly two weeks.
FDA’s current Clinical Decision Support Software guidance is dated 2026-01-29 and supersedes the 2026-01-06 version. The non-device CDS exclusion requires all four statutory criteria; the company’s citation of 2022 guidance is not a current FDA determination for Endobits.
The visually inspected FDA guidance page8 treats repeated CGM measurements as a pattern; software assessing the clinical implications or relevance of that pattern fails Criterion 1. Assessing Endobits requires its specific version, function and intended use. This is a classification question, not a company compliance finding.
FDA’s current Clinical Decision Support Software guidance is dated 2026-01-29 and supersedes the 2026-01-06 version. The non-device CDS exclusion requires all four statutory criteria; the company’s citation of 2022 guidance is not a current FDA determination for Endobits.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The visually inspected FDA guidance page8 treats repeated CGM measurements as a pattern; software assessing the clinical implications or relevance of that pattern fails Criterion 1. Assessing Endobits requires its specific version, function and intended use. This is a classification question, not a company compliance finding.
Supports: Profile · dual use posture
The visually inspected FDA guidance page8 treats repeated CGM measurements as a pattern; software assessing the clinical implications or relevance of that pattern fails Criterion 1. Assessing Endobits requires its specific version, function and intended use. This is a classification question, not a company compliance finding.
FDA’s current Clinical Decision Support Software guidance is dated 2026-01-29 and supersedes the 2026-01-06 version. The non-device CDS exclusion requires all four statutory criteria; the company’s citation of 2022 guidance is not a current FDA determination for Endobits.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
FDA’s current Clinical Decision Support Software guidance is dated 2026-01-29 and supersedes the 2026-01-06 version. The non-device CDS exclusion requires all four statutory criteria; the company’s citation of 2022 guidance is not a current FDA determination for Endobits.
The visually inspected FDA guidance page8 treats repeated CGM measurements as a pattern; software assessing the clinical implications or relevance of that pattern fails Criterion 1. Assessing Endobits requires its specific version, function and intended use. This is a classification question, not a company compliance finding.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The visually inspected FDA guidance page8 treats repeated CGM measurements as a pattern; software assessing the clinical implications or relevance of that pattern fails Criterion 1. Assessing Endobits requires its specific version, function and intended use. This is a classification question, not a company compliance finding.
Supports: Endobits clinician CGM review and care-workflow platform · core features
FDA’s current Clinical Decision Support Software guidance is dated 2026-01-29 and supersedes the 2026-01-06 version. The non-device CDS exclusion requires all four statutory criteria; the company’s citation of 2022 guidance is not a current FDA determination for Endobits.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The visually inspected FDA guidance page8 treats repeated CGM measurements as a pattern; software assessing the clinical implications or relevance of that pattern fails Criterion 1. Assessing Endobits requires its specific version, function and intended use. This is a classification question, not a company compliance finding.
Supports: Endobits clinician CGM review and care-workflow platform · summary
FDA’s current Clinical Decision Support Software guidance is dated 2026-01-29 and supersedes the 2026-01-06 version. The non-device CDS exclusion requires all four statutory criteria; the company’s citation of 2022 guidance is not a current FDA determination for Endobits.
ClinicalTrials.gov NCT04217369 describes a planned randomized comparison of Diabits with and without forecasts. Its current status is UNKNOWN; last known status is NOT_YET_RECRUITING, last posted update is 2020-01-03, and hasResults is false. The sponsor name is Bio Conscious Technologies Ltd in this historical record.
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
Supports: Profile · operating context
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
Supports: Endobits clinician CGM review and care-workflow platform · technicaldomainslugs
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
Supports: Endobits clinician CGM review and care-workflow platform · display lead
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The primary-care page offers a web SaaS workflow without additional sensor hardware: ranked panels, CGM review, draft charts and RPM/CCM documentation. The provider pages market EHR connections including eClinicalWorks, Cerner, athenahealth, OSCAR and Cliniko; no public contract establishes every integration’s deployed scope.
The current company footer identifies Vancouver and explicitly says the software is used under clinician oversight on FDA-cleared glucose monitors and is not itself a diagnostic device or substitute for diagnosis or treatment.
The current company footer identifies Vancouver and explicitly says the software is used under clinician oversight on FDA-cleared glucose monitors and is not itself a diagnostic device or substitute for diagnosis or treatment.
Supports: Profile · operating context
The current company footer identifies Vancouver and explicitly says the software is used under clinician oversight on FDA-cleared glucose monitors and is not itself a diagnostic device or substitute for diagnosis or treatment.
The current company footer identifies Vancouver and explicitly says the software is used under clinician oversight on FDA-cleared glucose monitors and is not itself a diagnostic device or substitute for diagnosis or treatment.
The current company footer identifies Vancouver and explicitly says the software is used under clinician oversight on FDA-cleared glucose monitors and is not itself a diagnostic device or substitute for diagnosis or treatment.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The current company footer identifies Vancouver and explicitly says the software is used under clinician oversight on FDA-cleared glucose monitors and is not itself a diagnostic device or substitute for diagnosis or treatment.
The company describes Companion 5 as the patient app reading Apple Health sensor data and sharing forecasts with an invited clinic, while clinics use the web application. The page contains an explicit unresolved note to confirm the App Store release date, so August 1 should not be treated as independently confirmed release timing.
The company describes Companion 5 as the patient app reading Apple Health sensor data and sharing forecasts with an invited clinic, while clinics use the web application. The page contains an explicit unresolved note to confirm the App Store release date, so August 1 should not be treated as independently confirmed release timing.
The company describes Companion 5 as the patient app reading Apple Health sensor data and sharing forecasts with an invited clinic, while clinics use the web application. The page contains an explicit unresolved note to confirm the App Store release date, so August 1 should not be treated as independently confirmed release timing.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The company describes Companion 5 as the patient app reading Apple Health sensor data and sharing forecasts with an invited clinic, while clinics use the web application. The page contains an explicit unresolved note to confirm the App Store release date, so August 1 should not be treated as independently confirmed release timing.
The company describes Companion 5 as the patient app reading Apple Health sensor data and sharing forecasts with an invited clinic, while clinics use the web application. The page contains an explicit unresolved note to confirm the App Store release date, so August 1 should not be treated as independently confirmed release timing.
The company describes Companion 5 as the patient app reading Apple Health sensor data and sharing forecasts with an invited clinic, while clinics use the web application. The page contains an explicit unresolved note to confirm the App Store release date, so August 1 should not be treated as independently confirmed release timing.
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Supports: Profile · display lead
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Supports: Profile · dual use posture
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Supports: Profile · operating context
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Supports: Endobits clinician CGM review and care-workflow platform · summary
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Supports: Endobits clinician CGM review and care-workflow platform · core features
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
Supports: Endobits clinician CGM review and care-workflow platform · display lead
Terms effective July 2026 say provider services are intended for qualified healthcare professionals, who retain independent clinical judgment. Billing codes are informational, and eligibility, coverage and claims remain the provider’s responsibility.
The federal corporate record gives the registered office as 1055 Dunsmuir Street, Suite 3000, Vancouver, BC V7X1K8, Canada. This establishes a Canadian legal office, not an operating facility or laboratory.
Supports: Profile · canadian footprint
Corporations Canada lists Bio-Conscious Technologies Inc., corporation 922906-0, business number 806014585RC0001, as Active under the Canada Business Corporations Act. Its certificate of incorporation is dated 2015-03-22.
ClinicalTrials.gov NCT04614376 lists an observational Alzheimer/CGM study sponsored by Bio Conscious Technologies Inc. Its current overall status is UNKNOWN; the last known status is RECRUITING, the last posted update is 2020-11-04, and hasResults is false. Estimated dates are not actual completion evidence.
Supports: Profile · profileData.portfolioScope
ClinicalTrials.gov NCT04614376 lists an observational Alzheimer/CGM study sponsored by Bio Conscious Technologies Inc. Its current overall status is UNKNOWN; the last known status is RECRUITING, the last posted update is 2020-11-04, and hasResults is false. Estimated dates are not actual completion evidence.
The corporate science page discusses glucose and aging mechanisms and positions Endobits as clinician-supervised decision support rather than a diagnostic device. The Alzheimer development funding and stale trial registration do not establish a validated dementia-diagnostic product.
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
Supports: Profile · operating context
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
Supports: Profile · commercial status
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
Supports: Endobits clinician CGM review and care-workflow platform · maturity
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
The payer page says U.S. primary-care panels are live but offers references under NDA. It proposes 12-month outcome-linked pilots against a jointly fixed trailing-12-month acute-event baseline. This is an advertised pilot structure; the page supplies no named current buyer or signed pilot.
True North Map applies the commercial company category to Bio-Conscious Technologies from its documented mandate and source-bounded operating evidence.
Supports: Profile · current activity as of
Pacific Economic Development Canada's dated record anchors this activity to 2026-05-11.
Supports: Profile · dual use posture
Endobits diabetes decision-support platform has documented civilian or industrial applications and a bounded potential relevance to Canadian defence, security or strategic-infrastructure needs.
Supports: Profile · disclosed financing summary
PacifiCan’s 2026-05-11 backgrounder names Vancouver’s Bio-Conscious and CAD 1.5 million to commercialize Endobits for hospitals in Canada and the U.S. This states programme intent; it does not establish accepted deployment in a Canadian hospital.
True North Map derives a first-conversation question about Endobits diabetes decision-support platform configuration and accepted outcomes from the documented maturity boundary.
Do not describe Endobits as a diagnostic device; verify Canadian deployments, privacy/data-residency controls, clinical outcomes, and vendor-reported revenue or patient metrics. The first conversation should therefore separate current offer, development evidence and accepted operational use.
Supports: Profile · current activity
On May 11, 2026, PacifiCan announced $1.5 million to support commercialization of the company's AI-enabled diabetes-care software.
Supports: Profile · canadian footprint
Bio-Conscious Technologies publishes an operating presence in Vancouver, British Columbia, Canada, and its current public record anchors Endobits diabetes decision-support platform to that Canadian organization.
Supports: Profile · description
True North Map derives this executive description for Bio-Conscious Technologies from the official identity and technical records together with Pacific Economic Development Canada's corroborating evidence.
Supports: Profile · organization categories
True North Map applies the dual use category to Bio-Conscious Technologies from its documented mandate and source-bounded operating evidence.
Supports: Endobits clinician CGM review and care-workflow platform · maturity
Pacific Economic Development Canada's public evidence confirms a company-specific project, award, program or operating context, while configuration-specific acceptance and scale remain bounded by the reviewer warning.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s 2026-05-11 backgrounder names Vancouver’s Bio-Conscious and CAD 1.5 million to commercialize Endobits for hospitals in Canada and the U.S. This states programme intent; it does not establish accepted deployment in a Canadian hospital.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s 2026-05-11 backgrounder names Vancouver’s Bio-Conscious and CAD 1.5 million to commercialize Endobits for hospitals in Canada and the U.S. This states programme intent; it does not establish accepted deployment in a Canadian hospital.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s 2026-05-11 backgrounder names Vancouver’s Bio-Conscious and CAD 1.5 million to commercialize Endobits for hospitals in Canada and the U.S. This states programme intent; it does not establish accepted deployment in a Canadian hospital.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s 2026-05-11 backgrounder names Vancouver’s Bio-Conscious and CAD 1.5 million to commercialize Endobits for hospitals in Canada and the U.S. This states programme intent; it does not establish accepted deployment in a Canadian hospital.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s 2026-05-11 backgrounder names Vancouver’s Bio-Conscious and CAD 1.5 million to commercialize Endobits for hospitals in Canada and the U.S. This states programme intent; it does not establish accepted deployment in a Canadian hospital.
Bio-Conscious Technologies operates from Vancouver, British Columbia, with a public mandate centred on Endobits diabetes decision-support platform; public sources do not establish every customer, configuration or operational outcome.
Supports: Profile · profileData.portfolioScope
Bio-Conscious Technologies's documented portfolio in this dossier is bounded to Endobits diabetes decision-support platform and the source-backed functions listed below.
Supports: Profile · commercial status
Bio-Conscious Technologies currently presents Endobits diabetes decision-support platform as part of its public commercial offering.
Supports: Endobits clinician CGM review and care-workflow platform · core features
Automated CGM data ingestion and risk prioritization
Remote chronic-care delivery and clinical workflow
Supports: Endobits clinician CGM review and care-workflow platform · summary
Endobits connects to supported continuous-glucose-monitor sources and helps care teams prioritize patients, review trends, and document remote care. The company states that it is decision-support software rather than a diagnostic medical device.
Supports: Endobits clinician CGM review and care-workflow platform · capability type
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
Supports: Profile · disclosed financing summary
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
NRC’s disclosure lists a CAD 49,420 contribution, agreement 969177, to the same recipient BN 806014585 from 2021-06-15 to 2021-12-17. Its purpose was design and development of two software components for ML-based Alzheimer detection using CGM data. This funds development, not a validated diagnostic offering.
The pricing page advertises a free individual app/report, optional Watch from USD 19/month, primary care from USD 29/patient/month, endocrinology from USD 39.99/patient/month and payer plans from USD 9.99/member/month. Provider billing is based on active patients with unlimited clinician seats.
Supports: Profile · description
The pricing page advertises a free individual app/report, optional Watch from USD 19/month, primary care from USD 29/patient/month, endocrinology from USD 39.99/patient/month and payer plans from USD 9.99/member/month. Provider billing is based on active patients with unlimited clinician seats.
Supports: Profile · commercial status
The pricing page advertises a free individual app/report, optional Watch from USD 19/month, primary care from USD 29/patient/month, endocrinology from USD 39.99/patient/month and payer plans from USD 9.99/member/month. Provider billing is based on active patients with unlimited clinician seats.
Supports: Profile · company stage
The pricing page advertises a free individual app/report, optional Watch from USD 19/month, primary care from USD 29/patient/month, endocrinology from USD 39.99/patient/month and payer plans from USD 9.99/member/month. Provider billing is based on active patients with unlimited clinician seats.
The pricing page advertises a free individual app/report, optional Watch from USD 19/month, primary care from USD 29/patient/month, endocrinology from USD 39.99/patient/month and payer plans from USD 9.99/member/month. Provider billing is based on active patients with unlimited clinician seats.
Federal disclosure records $1.5 million for Bio-Conscious Technologies to commercialize an AI diabetes-management platform, under agreement PC0012694 running March 20, 2026 to March 31, 2028.
PacifiCan’s proactive-disclosure record lists a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, under REGI; agreement PC0012694 runs 2026-03-20 to 2028-03-31 to support commercialization of AI technologies for diabetes treatment. The record is an agreement disclosure, not proof of full disbursement or equity investment.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
PacifiCan’s proactive-disclosure record lists a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, under REGI; agreement PC0012694 runs 2026-03-20 to 2028-03-31 to support commercialization of AI technologies for diabetes treatment. The record is an agreement disclosure, not proof of full disbursement or equity investment.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s proactive-disclosure record lists a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, under REGI; agreement PC0012694 runs 2026-03-20 to 2028-03-31 to support commercialization of AI technologies for diabetes treatment. The record is an agreement disclosure, not proof of full disbursement or equity investment.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s proactive-disclosure record lists a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, under REGI; agreement PC0012694 runs 2026-03-20 to 2028-03-31 to support commercialization of AI technologies for diabetes treatment. The record is an agreement disclosure, not proof of full disbursement or equity investment.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s proactive-disclosure record lists a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, under REGI; agreement PC0012694 runs 2026-03-20 to 2028-03-31 to support commercialization of AI technologies for diabetes treatment. The record is an agreement disclosure, not proof of full disbursement or equity investment.
Supports: PacifiCan REGI contribution funding event
PacifiCan’s proactive-disclosure record lists a CAD 1,500,000 contribution to Bio-Conscious Technologies Inc., BN 806014585, under REGI; agreement PC0012694 runs 2026-03-20 to 2028-03-31 to support commercialization of AI technologies for diabetes treatment. The record is an agreement disclosure, not proof of full disbursement or equity investment.
MTEC’s life-sciences directory lists Bio-Conscious in Vancouver and describes CGM predictive software and API services. The listing provides no contract, accepted defence deployment or explicit proof of MTEC membership; its employee-size/address fields should not override current authoritative records.
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
Supports: Endobits clinician CGM review and care-workflow platform · maturity
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The performance page describes 1–11-hour prediction results as internal validation available through an NDA evidence brief, and explicitly distinguishes peer-reviewed 60-minute results from longer-horizon ongoing validation. Forecast accuracy, clinical effect and independent validation must remain separate.
The company’s 2024-04-25 press release announces GPT-4 integration in Endobits V5 for tailored chart notes drawing on CGM review and ADA guidelines. Provider-reviewed documentation is the supported mechanism; producer claims of care improvement are not independent outcome evidence.
Supports: Endobits clinician CGM review and care-workflow platform · summary
The company’s 2024-04-25 press release announces GPT-4 integration in Endobits V5 for tailored chart notes drawing on CGM review and ADA guidelines. Provider-reviewed documentation is the supported mechanism; producer claims of care improvement are not independent outcome evidence.
The company’s 2024-04-25 press release announces GPT-4 integration in Endobits V5 for tailored chart notes drawing on CGM review and ADA guidelines. Provider-reviewed documentation is the supported mechanism; producer claims of care improvement are not independent outcome evidence.
Supports: Endobits clinician CGM review and care-workflow platform · core features
The company’s 2024-04-25 press release announces GPT-4 integration in Endobits V5 for tailored chart notes drawing on CGM review and ADA guidelines. Provider-reviewed documentation is the supported mechanism; producer claims of care improvement are not independent outcome evidence.
Continue exploring
Follow the strongest connections
Continue through related organizations, reviewed mission and Defence need connections, programme pathways, and explicitly linked intelligence. Similarity results describe shared areas of work, not partnerships or endorsements.
Organizations
Profiles that provide the strongest reviewed or discovery-led continuation.
